Tag: SNM
Medtronic files complaint against Axonics to stop “unauthorised use” of neuromodulation...
Medtronic recently announced that it has filed a complaint with the US International Trade Commission (ITC), along with a parallel action in US District...
Axonics gains Health Canada approval for fourth-generation rechargeable sacral neuromodulation system
Axonics has announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system as a treatment for bladder and bowel dysfunction.
The newly...
Neuspera announces first successful Nuvella system implant in second phase of...
Neuspera Medical has announced the first patient has been successfully implanted with the Nuvella system in its pivotal SANS-UUI clinical trial, which will evaluate...
Axonics announces first patient implants in Canada with recharge-free sacral neuromodulation...
Axonics has announced the first patient implants in Canada with Axonics F15, the company’s newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system.
The University...
Axonics receives FDA approval for new recharge-free sacral neuromodulation system
Axonics has announced that the US Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator, the...
Medtronic receives FDA approval for InterStim X system for bladder and...
Medtronic has announced receipt of approval from the US Food and Drug Administration (FDA) for its new, recharge-free InterStim system—with the device being made...
Medtronic announces US launch of its InterStim Micro neurostimulator
Medtronic has announced that its recently US Food and Drug Administration (FDA)-approved InterStim Micro neurostimulator for sacral neuromodulation (SNM) therapy is now available in...
Axonics granted six US patents and allowed three additional patents related...
Axonics has announced that the United States Patent and Trademark Office has issued or allowed Axonics nine US utility patents in 2019, along with...
Axonics provides survey results from Physician Seminar Series showcasing the recently...
Axonics, a medical technology company that has developed and is commercialising novel implantable Sacral Neuromodulation (SNM) devices for the treatment of bladder and bowel...
Axonics announces first commercial US patient implanted with its sacral neuromodulation...
Axonics has announced the first US-based implantation of the Axonics r-SNM system subsequent to its clearance by the US Food & Drug Administration (FDA)...
Axonics announces agreement to supply sacral neuromodulation systems to leading urology...
Axonics has announced that it has entered into an exclusive agreement to supply the Axonics rechargeable sacral neuromodulation (r-SNM) system to Adult Pediatric Urology...
